

ALLIGATOR BIOSCIENCE ANNOUNCES PUBLICATION HIGHLIGHTING ITS RUBY® BISPECIFIC ANTIBODY FORMAT IN THE SCIENTIFIC JOURNAL "MABS"

Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces the publication of a scientific article featuring its novel bispecific antibody format RUBY® in the peer-reviewed journal mAbs.

- RUBY® is a novel bispecific antibody format with excellent functionality including IgG-like stability, pharmacology and developability properties
- The RUBY® format allows rapid generation of bispecific antibodies (bsAbs) that fulfill key drug development criteria and mitigates many of the challenges associated to other bsAb formats

The article, entitled "**RUBY® - A tetravalent (2+2) bispecific antibody format with excellent functionality and IgG-like stability, pharmacology and developability properties**", highlights how:

- RUBY® allows rapid generation of bsAbs with high developability
- RUBY® bsAbs are compatible with small-scale production systems for screening purposes, can be produced at high yields from production cell lines, contain low amounts of aggregates, display favorable solubility and stress endurance profiles, are compatible with various IgG isotypes, and allows for tailored Fc gamma receptor interactions
- Retained interaction with Fc neonatal receptors is demonstrated to translate into a mAb-like pharmacokinetic profile
- Functionality of conditionally active RUBY® bsAbs is confirmed *in vitro*, and RUBY® bsAbs are shown to penetrate and localize to tumor tissue *in vivo*

*"The publication of this article in the renowned scientific journal mAbs is an important recognition of our bispecific antibody format RUBY®. It demonstrates its great developability and its place as a key part of our proprietary drug discovery engine for the development of innovative drugs for hard-to-treat cancers," said **Laura von Schantz, CTO at Alligator Bioscience.** "The article in particular demonstrates how our RUBY® format has attractive mAb-like attributes and offers the possibility to mitigate many of the development and bioprocessing challenges linked to other bsAb formats, facilitating both high functionality and developability and making it a valuable contributor to the next generation of bsAbs."*

PRESS RELEASE

26 March 2024 08:30:00 CET



Alligator's RUBY® format is an important proprietary technology used both in internal and partnered programs.

The full article is available online via [this link](#).

For further information, please contact:

Søren Bregenholt, CEO

E-mail: soren.bregenholt@alligatorbioscience.com

Phone: +46 (0) 46 540 82 00

LifeSci Advisors

Investor Relations

Guillaume van Renterghem

E-mail: gvanrenterghem@lifesciadvisors.com

Phone: +41 (0) 76 735 01 31

About Alligator Bioscience

Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator's portfolio includes several promising drug candidates, with the CD40 agonist mitazalimab as its key asset. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its proprietary technology platform, Neo-X-Prime®, and novel drug candidates based on the RUBY® bispecific platform with Orion Corporation. Out-licensed programs include AC101/HLX22, in Phase 2 development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc.

Alligator Bioscience's shares are listed on Nasdaq Stockholm (ATORX) and is headquartered in Lund, Sweden.

For more information, please visit alligatorbioscience.com.

Attachments

[Alligator Bioscience Announces Publication Highlighting its RUBY® Bispecific Antibody Format in the Scientific Journal "mAbs"](#)